**** CELERA - NEWS **** - 500 Beiträge pro Seite

[MR_MAKERICH]

Hallo Trader,

Es gibt NEWS bei Celera !!!

Vom 29.6.2000 :

DEAL in Australien!
Demnach sollen Nutzungsverträge mit Celera ausgehandelt werden.

Das bedeutet: UMSATZ und ERTRAGSSTEIGERUNG !!!

Thursday June 29, 12:01 am Eastern Time
Company Press Release
Celera Genomics Enters Into Database Subscription for Publicly Funded Australian Research Institutions
ROCKVILLE, Md.--(BW HealthWire)--June 29, 2000--Celera Genomics (NYSE:CRA - news), a PE Corporation business, has signed an agreement with the government of Australia acting through the Australian National Health and Medical Research Council (NHMRC), that provides a multi-year subscription to five of Celera`s current databases, which includes Celera`s advanced bioinformatics tools and browsers. Through this agreement the NHMRC can provide subscriptions to its publicly funded research institutions. Financial terms of the agreement were not disclosed.

``We are pleased to partner with the world-renowned NHMRC and its premier research institutions within Australia,`` said J. Craig Venter, Ph.D., Celera`s president and chief scientific officer. ``By tapping into the web-based Celera Discovery System, researchers around the world can now have immediate access to Celera`s growing genomic databases. This agreement is also important because it opens the doors to future research collaborations between Celera and these Australian research institutions.``

``This means that Australian researchers from our major publicly-funded institutions, will be among the first in the world to work with Celera`s breakthrough information technology, namely its extensive database, computing infrastructure, and advanced computer search capacities,`` said Dr. Warwick Anderson, Chairman of the Research Committee of the NHMRC. ``This arrangement is particularly exciting for Celera`s technology is believed to be of the highest standard and the agreement should allow rapid dissemination of crucial genetic information to publicly funded researchers.``

``This agreement is yet further confirmation of the Australian Government`s commitment and vision in investing in health and medical research through the NHMRC, which is increasingly being acknowledged as an internationally renowned leader in world health and research affairs,`` said Dr. Michael Wooldridge, Federal Health Minister, Australian Government.

The NHMRC`s database subscription will provide access to the Celera Discovery System which includes a comprehensive set of bioinformatics systems and tools for viewing, browsing and analyzing genomic information. The NHMRC will have access to five of Celera`s databases, which include proprietary information integrated with publicly available data. First, the Celera Human Gene Index provides customers with the set of human genes derived from EST sequencing programs. Second, the Drosophila Genome Database provides the complete sequence of the Drosophila melanogaster genome generated by Celera`s whole genome shotgun sequencing strategy. The Drosophila Genome Database is extensively annotated with gene, protein, and biological information. Third, Celera`s Human Genome Database is expected to provide the complete sequence of the human genome and the entire collection of human genes with links to associated biological and disease information. Fourth, Celera intends for its SNP Database to be the single most comprehensive source of single nucleotide polymorphisms, the major form of DNA variation responsible for human traits, certain illnesses, and variable drug safety and efficacy. This database may include SNP data from the sequencing of several individuals. Fifth, the Mouse Genome Database being generated by Celera should allow for comparative analysis with the human genome that may be especially significant for the identification of genes and gene regulatory regions of importance to understanding human biology.

Australia`s NHMRC is a statutory authority established under the National Health and Medical Research Council Act of 1992. The Act sets down four statutory obligations for the NHMRC: 1) To raise the standard of individual and public health throughout Australia; 2) To foster the development of consistent health standards between the Australian States and Territories; 3) To foster medical research and training and public health research and training throughout Australia; and 4) To foster consideration of ethical issues relating to health.

As the pre-eminent national organization combining research funding and health and health ethics advice, the NHMRC draws together the sometimes conflicting views of all the components of the health system, governments, medical practitioners, nurses and allied health professionals, researchers, teaching and research institutions, public and private managers, programs managers, service administrators, community health organizations, social health researchers, and ultimately, consumers.

[klausdieter99]

Eine weitere Zeitungsmeldung bzgl. des Deals mit Australia mit einer Äußerung von Craig Venter die bisher noch nicht gepostet wurde.



kleiner Tip: die Spitze des Eisberges...




Australia.


The news, disclosed early this morning in the Australian Parliament, comes as the Rockville company struggles to convince Wall Street it has a product that people might want to buy.

The deal with Australia`s National Health and Medical Research Council creates a standard mechanism by which any academic or nonprofit research institution in the country can gain access to Celera`s genetic databases of the human and of two important research organisms, the fruit fly and the mouse. With the fees heavily subsidized by the Australian government, a large majority of research institutions are expected to take advantage of the offer. Celera did not disclose financial terms.

"This arrangement is particularly exciting for Australian researchers," Warwick Anderson, chairman of Australia`s main research committee, said in a statement, "as Celera`s technology is believed to be of the highest standard and the agreement should allow rapid dissemination of crucial genetic information to publicly funded researchers."

The deal is the latest development in a tumultuous week for Celera. The company`s president and chief scientific officer, J. Craig Venter, stood with his publicly financed rival, Francis Collins, at the White House on Monday as President Clinton announced that their respective groups had put together the first maps of the human genome.

The company spent the rest of the week trying to reassure nervous investors, who drove the stock down 21 percent in two days amid fears that Celera would not be able to follow its scientific triumph with a workable business plan. The stock bounced upward yesterday as rumors began to circulate about the Australian deal.

Venter said the timing was unrelated to the market dip but he hopes that signing up an entire country`s scientists as customers will go some way toward alleviating investor concerns.

"I haven`t been fooling when I say we`ve had a lot of discussions going on with a lot of places," he said. "This is the tip of the iceberg."

Venter and colleagues turned the world of gene research upside down two years ago when they announced that they would create a private company to decode the exact sequence of chemicals in the human genome, the master blueprint of life, beating publicly funded researchers to the goal. They were met with withering skepticism in the scientific world that they could pull it off and equal skepticism in the business world that they could make money doing so.

Monday`s announcement in the East Room of the White House--which followed an agreement by the rival camps to quit fighting and call the race a tie--appears to have alleviated the first concern, but not the second. Since Celera plans to give away raw data about the human genome, investors seem to be at a loss as to how it will make money.

Celera`s answer is that the giveaway is a loss leader that can attract scientists to the company`s more elaborate paid offerings. These include robust tools for analyzing the human genome and, at least as significant, a map of the genome of the mouse by late this year. Mice are a critical experimental organism in biology, and the mouse genome is expected to shed crucial light on the origin and function of human genes.

More and more scientists, as they learn the full scope of Celera`s plans, seem to be afraid not to sign up. Vanderbilt University recently became the first academic institution to cut a deal with Celera. Immunex Corp. of Seattle this week became the first biotechnology company to do so. A half-dozen big pharmaceutical companies have already signed up for fees as high as $15 million a year. Celera is known to be negotiating with numerous parties, including other countries that want to sign up all their scientists at once.

"Academics are competitive people," said Paul Gilman, Celera`s director of policy planning. "They get that we`ve got data and we`ve got good data. Then we drop on them the mouse thing and they go `Holy mackerel!` "





Celera stock rose yesterday for the first time this week, closing at $108.50, a one-day gain of 9 percent.



Sollte die Investierten eigentlich sehr optimistisch stimmen.